References
- The Korean Academy of Tuberculosis and Respiratory Diseases. The treatment guideline of tuberculosis. 4th ed. Seoul: The Korean Academy of Tuberculosis and Respiratory Diseases; 2005.
- Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis druginduced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192-202. https://doi.org/10.1111/j.1440-1746.2007.05207.x
- Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11:699-707. https://doi.org/10.1111/j.1440-1843.2006.00941.x
- Moon DS, Jang TW, Oak CH, Jung MH, Yoo CH, Song JY, et al. A case of pyrazinamide induced fulminant hepatic failure. Tuberc Respir Dis 2007;63:435-9. https://doi.org/10.4046/trd.2007.63.5.435
- McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33. https://doi.org/10.1086/444463
- Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6. https://doi.org/10.1016/0168-8278(90)90124-A
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7. https://doi.org/10.1164/rccm.200206-626OC
- Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7.
- Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:648-55.
- Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010;14:275-81.
- Surucuoglu S, Ozkutuk N, Celik P, Gazi H, Dinc G, Kurutepe S, et al. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome. Ann Saudi Med 2005;25:313-8.
- Hyun JH, Kim JG, Jo SK, Yun IC. A case of toxic hepatitis induced prothionamide (TH-1321) and ethambutol. Korean J of Gastroenterol 1970;2:21-7.
- Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. https://doi.org/10.1164/rccm.167.4.603
- Marzuki OA, Fauzi AR, Ayoub S, Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008;49:688-93.